ReviewDrugs2006
Mitomycin: clinical applications in ophthalmic practice.
Review in Drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Formulation of treatment protocol for ocular surface squamous neoplasia.International ophthalmology · 2026Pooled it
- Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Topical Mitomycin C in functional endoscopic sinus surgery.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2012Trial
- Topical Mitomycin C Chemotherapy After Surgical Resection of Conjunctival Amelanotic Melanoma in a Dog.Veterinary ophthalmology · 2026Article
- The effect of mitomycin-C on 3 snip punctoplasty.International ophthalmology · 2026Article
- Off-label prescribing in ophthalmology: a retrospective analysis.Frontiers in pharmacology · 2026Article
- The Role of Biodegradable Collagen Matrices in Glaucoma Filtration Surgery: Practical Considerations in the Post-Ologen Era.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Glaucoma drainage device erosion rescued with upper eyelid forniceal conjunctival pedicle flap.American journal of ophthalmology case reports · 2025Article
- Influence of Solvent Choice on Mitomycin C Loading and Stability in Electrospun Polyvinylidene Fluoride Nanofibers.ACS omega · 2025Article
- Inappropriate administration of mitomycin in a cataract patient.American journal of ophthalmology case reports · 2025Article
- Gynecologic postoperative anti-adhesion barriers: From biomaterials to barrier development.Biomaterials and biosystems · 2025Review
- Topical Mitomycin C Application Following Surgical Excision in Canine Oral Papilloma: A Case Report.Veterinary medicine and science · 2025Article
- Update in the Diagnosis and Management of Ocular Surface Squamous Neoplasia (OSSN).Journal of clinical medicine · 2025Review
- Oncological principles in the management of ocular surface squamous neoplasia - A Review.Indian journal of ophthalmology · 2025Review
- Conjunctival melanoma: comprehensive insights into clinical features, genetic alterations, and modern treatment approaches.Pathology oncology research : POR · 2025Review
- Can Epirubicin Be Used in Laryngology Practice Like Mitomycin? An Experimental and Pioneering Study.Iranian journal of otorhinolaryngology · 2025Article
- Evaluation of the cytotoxic and genotoxic/antigenotoxic effects of resveratrol in human limbal explant cultures.International ophthalmology · 2023Article
- FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.Molecules (Basel, Switzerland) · 2022Review
- Determination of the Protein-Protein Interactions within Acyl Carrier Protein (MmcB)-Dependent Modifications in the Biosynthesis of Mitomycin.Molecules (Basel, Switzerland) · 2021Article
- Ocular surface squamous neoplasia: management and outcomes.Eye (London, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitomycin (mitomycin C; MMC) is an antibiotic isolated from Streptomyces caespitosus. The drug is a bioreductive alkylating agent that undergoes metabolic reductive activation, and has various oxygen tension-dependent cytotoxic effects on cells, including the cross-linking of DNA. It is widely used systemically for the treatment of malignancies, and has gained popularity as topical adjunctive therapy in ocular and adnexal surgery over the past 2 decades. In ophthalmic medicine, it is principally used to inhibit the wound healing response and reduce scarring of surgically fashioned ostia. Hence, it has been used as adjunctive therapy in various ocular surgeries, such as glaucoma filtering surgeries, dacryocystorhinostomy, corneal refractive surgery and surgeries for ocular cicatrisation. In addition, it has been used as an adjunct in the surgical management of pterygia, ocular surface squamous neoplasia, primary acquired melanosis with atypia and conjunctival melanoma. In many of these surgeries and ophthalmic pathologies, MMC showed a significant beneficial effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.